Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (PIRAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02921685|
Recruitment Status : Unknown
Verified September 2018 by Institut Paoli-Calmettes.
Recruitment status was: Recruiting
First Posted : October 3, 2016
Last Update Posted : September 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hematologic Malignancies||Drug: Monalizumab||Phase 1|
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for most of hematological malignancies, though the graft-versus-tumor (GVT) effect mediated by immune cells from the donor. However, the use of Allo-HSCT is limited by its toxicity, notably the graft-versus-host disease (GVHD) that is a major cause of non-relapse mortality (NRM). Conditioning regimens dramatically improved during the last fifteen years, with a decrease of both GVHD and NRM rates. Now, disease recurrence after Allo-HSCT is the first cause of treatment failure and remains a concern for approximately 30% of the patients.
Based on a safety immunologic platform (ATG based reduced toxicity conditioning regimens), it is needed to develop post Allo-HSCT strategies to decrease the incidence of relapse. In this context, the modulation of immune cell activity could play a role to prevent relapse. NK cells have a unique capacity to exert potent GVT effects without inducing GVHD. Moreover, NK cells recovery occurs early after Allo-HSCT and NK cells function are not severely impaired by the use of ciclosporin A, that is given for few months after Allo-HSCT as GVHD prophylaxis. Thus, NK cell modulation appears as a viable option for early immune intervention after Allo-HSCT.
Monalizumab (IPH2201), a monoclonal antibody has a non-depleting and purely blocking activity directed with high affinity and specificity against the CD94/NKG2A receptor expressed by subsets of NK cells, activated αβ CD8+ T cells, γδ-T cells and NK T cells. By suppressing the inhibitory signal transduced by NKG2A, IPH2201 enhances the anti-tumor functions, including cytolytic activity of these immune effector cells.The aim of the study is to determine the safety of IPH2201 after allogenic stem cell transplantation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning|
|Actual Study Start Date :||November 28, 2016|
|Estimated Primary Completion Date :||May 28, 2019|
|Estimated Study Completion Date :||April 28, 2020|
Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
Four dose levels will be tested.
- Occurence ratio of dose-limiting toxicity (DLT) [ Time Frame: 4 weeks ]
The occurrence of any of these 3 events will lead to the reporting of a Dose Limiting Toxicity:
- Any Grade ≥ 3 toxicity according to CTCAE attributable to IPH2201 administration, occurring within 4 weeks of IPH2201 administration and considered as relevant by the investigator
- Any grade ≥ II acute GVHD requiring a treatment by systemic corticosteroids and occurring within 4 weeks of IPH2201 administration.
- Any grade ≥ moderate chronic GVHD occurring within 4 weeks of IPH2201 administration.
- Incidence of acute GVHD of each grade or chronic GVHD of each degree of severity [ Time Frame: from D0 to Week 26 after administration of IPH2201 and at 1 year after transplantation ]Safety will be assessed using Glucksberg's classification for acute Graft versus host disease (GVHD) and NIH classification for chronic GVHD.
- Probabilities of non-relapse mortality (NRM) [ Time Frame: 1 year after the administration of IPH2201 ]
- Cumulative incidence of relapse (CIR) [ Time Frame: 1 year after administration of IPH2201. ]Efficacy endpoint
- Probability of Disease Free Survival (DFS) [ Time Frame: 1 year after the administration of IPH2201 ]Efficacy endpoint
- Probability of Overall survival (OS) [ Time Frame: 1 year after the administration of IPH2201 ]Efficacy endpoint
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02921685
|Contact: Dominique GENRE, MD||33 4 91 22 37 email@example.com|
|Contact: Margot BERLINE, MSc, MBA||33 4 91 22 37 firstname.lastname@example.org|
|Institut Paoli Calmettes||Recruiting|
|Marseille, Bouches Du Rhônes, France, 13009|
|Contact: Dominique GENRE, MD 33 4 91 22 37 78 email@example.com|
|Contact: Isabelle BOQUET, PhD 33 4 91 22 37 78 firstname.lastname@example.org|
|Sub-Investigator: Raynier DEVILLIER, MD|
|Principal Investigator:||Didier BLAISE, MD, PhD||Institut Paoli-Calmettes|